Personalized Cancer Care. Realized.
Forging a Clearer Path to Cancer Treatments
Covid-19 Updates: Allarity Therapeutics has partnered with Northern Arizona University to evaluate the antiviral activity of our PARP inhibitor Stenoparib (2X-121) for the potential treatment of COVID-19.
Allarity Therapeutics is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on the NASDAQ First North, Allarity (ALLR: SS) is headquartered in Horsholm, Denmark, with US operations, and is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.
Location: Clarion Malmö Live, Dag Hammarskjölds Torg 2, Malmö, Sweden/
Q1 2020 Conference Call
Time: 5:00pm CST